Abstract
As is diabetes itself, diabetic angiopathy is a multi-factorial disease. Advanced glycation endproducts (AGE) cause vascular cell derangement characteristic of diabetes, and this is mainly mediated by their interaction with receptor for AGE (RAGE). When made diabetic, RAGE-overexpressing transgenic mice exhibited exacerbation of the indices of nephropathy, and this was prevented by the inhibition of AGE formation. On the other hand, RAGE-deficient animals showed amelioration of diabetic nephropathy. Accordingly, AGE and RAGE should be regarded as environmental and cellular accounts and as a potential therapeutic target for diabetic nephropathy. In effect, substances that inhibit the formation of AGE, break preformed AGE, change metabolic flows away from glycation, antagonize RAGE, and capture RAGE ligands have been proven as effective remedies against this life-threatening disease.
Keywords: iNOS transgenic mice, endothelial cells, aminoguanidine, RAGE gene, diabetic nephropathy
Current Molecular Medicine
Title: RAGE in Diabetic Nephropathy
Volume: 7 Issue: 8
Author(s): Hiroshi Yamamoto, Takuo Watanabe, Yasuhiko Yamamoto, Hideto Yonekura, Seiichi Munesue, Ai Harashima, Kazuyo Ooe, Sharmin Hossain, Hidehito Saito and Naho Murakami
Affiliation:
Keywords: iNOS transgenic mice, endothelial cells, aminoguanidine, RAGE gene, diabetic nephropathy
Abstract: As is diabetes itself, diabetic angiopathy is a multi-factorial disease. Advanced glycation endproducts (AGE) cause vascular cell derangement characteristic of diabetes, and this is mainly mediated by their interaction with receptor for AGE (RAGE). When made diabetic, RAGE-overexpressing transgenic mice exhibited exacerbation of the indices of nephropathy, and this was prevented by the inhibition of AGE formation. On the other hand, RAGE-deficient animals showed amelioration of diabetic nephropathy. Accordingly, AGE and RAGE should be regarded as environmental and cellular accounts and as a potential therapeutic target for diabetic nephropathy. In effect, substances that inhibit the formation of AGE, break preformed AGE, change metabolic flows away from glycation, antagonize RAGE, and capture RAGE ligands have been proven as effective remedies against this life-threatening disease.
Export Options
About this article
Cite this article as:
Yamamoto Hiroshi, Watanabe Takuo, Yamamoto Yasuhiko, Yonekura Hideto, Munesue Seiichi, Harashima Ai, Ooe Kazuyo, Hossain Sharmin, Saito Hidehito and Murakami Naho, RAGE in Diabetic Nephropathy, Current Molecular Medicine 2007; 7(8) . https://dx.doi.org/10.2174/156652407783220769
DOI https://dx.doi.org/10.2174/156652407783220769 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Role of Endothelin in Diabetic Retinopathy
Current Vascular Pharmacology Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery
Current Neuropharmacology Relationships Between White Matter Hyperintensities, Cerebral Amyloid Angiopathy and Dementia in a Population-based Sample of the Oldest Old
Current Alzheimer Research Protein Conformational Pathology in Alzheimers and Other Neurodegenerative Diseases; New Targets for Therapy
Current Alzheimer Research Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Insulin-Degrading Enzyme: Structure-Function Relationship and its Possible Roles in Health and Disease
Current Pharmaceutical Design Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population
Current Alzheimer Research The Protective Effect of Jatrorrhizine Against Oxidative Stress in Primary Rat Cortical Neurons
CNS & Neurological Disorders - Drug Targets Molecular Links Between Endothelial Dysfunction and Neurodegeneration in Alzheimer's Disease
Current Alzheimer Research Adult Changes in Thought Study: Dementia is an Individually Varying Convergent Syndrome with Prevalent Clinically Silent Diseases that may be Modified by Some Commonly Used Therapeutics
Current Alzheimer Research Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews Incretins and Preservation of Endothelial Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Blockade of Ser16-Hsp20 Phosphorylation Attenuates Neuroprotection Dependent Upon Bcl-2 and Bax
Current Neurovascular Research Non-Alcoholic Fatty Liver Disease and Vascular Disease
Current Vascular Pharmacology Potential Role of Rho Kinase Inhibitors in Combating Diabetes-Related Complications Including Diabetic Neuropathy-A Review
Current Diabetes Reviews Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease
Current Alzheimer Research Connexins, Diabetes and the Metabolic Syndrome
Current Protein & Peptide Science History, Prevalence and Assessment of Limited Joint Mobility, from Stiff Hand Syndrome to Diabetic Foot Ulcer Prevention: A Narrative Review of the Literature
Current Diabetes Reviews Towards Newer Molecular Targets for Chronic Diabetic Complications
Current Vascular Pharmacology Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery